This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Polycomb group genes (PcGs) are epigenetic eff ectors involved in gene silencing. PcG activity
was fi rst recognized as essential for stem cell maintenance during embryo development.
Subsequently, several PcGs were shown to play a role in cancer initiation, progression, and
chemotherapy resistance. For example, PcG member BMI1 is up-regulated in prostate cancer
cells compared to normal counterparts, and mediates prostate cancer invasion and resistance
to chemotherapy. Another PcG member (EZH2) is up-regulated in high grade and high stage
breast, colorectal and brain tumors. At present, PcGs have been identifi ed as negative prognostic
markers in most human cancers. Easy-to-perform genetic analyses may pave the way to the
emergence of PcGs as cancer biomarkers. For example, Germinal EZH2 polymorphisms predict
lung cancer risk and colorectal cancer prognosis. Somatic EZH2 mutations were found to
drive B-cell lymphoma progression. In addition, a small molecule inhibitor of EZH2 showed
promising anti-tumor activity in breast, brain and prostate tumor models. Th us, PcGs may
emerge as novel prognostic and predictive markers in Oncology. Despite the well-recognized
role of PCGs in cancer cell biology, few researches explored the clinical potential of these genes.
In this presentation, I will summarize current evidence on PcGs and cancer, with particular
emphasis on what they can add to traditional oncology biomarkers. In addition, I will illustrate
a paradigm for rational development of PcG-targeting anticancer regimens, suggesting
specifi c therapeutic strategies. Hopefully, PcGs may emerge as novel prognostic and predictive
biomarker, as well as viable targets to target cancer initiation and metastatic spreading.
Francesco Crea has completed his MD in 2006 and his PhD in 2010 (both cum Laude) at Scuola Superiore
Sant?Anna, Pisa. He has spent 18 months at National Cancer Institute-Frederick (USA) as a Guest Scientist.
He is currently Lecturer in Clinical Pharmacology at Pisa University. There, he is directing a research project
on Polycomb genes in cancer. He has published more than 15 manuscripts on in peer-reviewed international
journals, including the Journal of Clinical Oncology, Trends in Pharmacological Sciences and Molecular Cancer
Therapeutics. He is Contributing Associate Editor-in Chief for the World Journal of Gastroenterology, and
Editorial writer for Epigenomics.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals